Fluocinolone Acetonide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Fluocinolone Acetonide
- Fluocinolone Acetonide: From Inflammatory Skin Diseases to Hypertrophic Lichen Planus
Fluocinolone Acetonide: From Inflammatory Skin Diseases to Hypertrophic Lichen Planus
One-Sentence Summary
Fluocinolone acetonide is a potent topical corticosteroid, originally used for inflammatory and itchy skin conditions such as atopic eczema, contact dermatitis, seborrheic dermatitis and lichen disease. The TxGNN model predicts it may be effective for hypertrophic lichen planus, but no clinical trials and no publications were found for this specific indication, so the prediction rests on model inference alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Inflammatory and itchy skin conditions (e.g. atopic eczema, contact dermatitis, seborrheic dermatitis, lichen disease). The Singapore licence records list no indication text, so this comes from the knowledge-graph indication list. |
| Predicted New Indication | Hypertrophic lichen planus |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Fluocinolone acetonide acts on the glucocorticoid receptor (NR3C1). Activating this receptor suppresses local inflammatory and immune activity, which is why the drug is used in creams for inflammatory and itchy skin disease. Detailed mechanism-of-action text was not available in the data compiled for this report, so this explanation rests on the receptor target and the drug's known class.
The drug is already linked to "lichen disease" among its original indications. Lichen planus is a T-cell-mediated inflammatory skin disease, so an anti-inflammatory and immunosuppressive effect is biologically plausible. The hypertrophic form is thick, itchy and persistent, and potent topical corticosteroids are a logical option for it.
The prediction is still a knowledge-graph inference. The data compiled for this report contain no trial or literature support for this subtype.
The model gave nearly identical scores (about 99.4%) to other lichen planus variants: lichen planus pigmentosus, annular atrophic lichen planus and lichen planus pemphigoides. This suggests the model is generalising from the approved "lichen disease" indication rather than from subtype-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for hypertrophic lichen planus.
Note: Best-Supported Alternative Prediction (Alopecia Areata)
Among the other top-10 predictions, only alopecia areata (TxGNN score 98.67%) has any supporting literature. All five items are historical, and only titles were available, so study design and outcomes could not be verified.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 4948970 | 1971 | RCT (double-blind per title; unverified) | Hifuka kiyo. Acta dermatologica | Topical treatment of alopecia areata comparing 0.025% and 1.2% fluocinolone acetonide cream |
| 4250339 | 1970 | Clinical efficacy assay | Dermatologica | 0.2% cream in alopecia areata and totalis; efficacy and side effects, including a localised acne-like reaction |
| 13947877 | 1963 | Case series | Archives of dermatology | Treatment of alopecia totalis with fluocinolone acetonide |
| 14071473 | 1963 | Clinical report | Archives of dermatology | Fluocinolone acetonide in a propylene glycol vehicle |
| 4268946 | 1973 | Clinical experience report | Fortschritte der Medizin | Experience with fluocinolone acetonide gel in skin diseases |
This evidence is old, small and of uncertain quality. There are no registered clinical trials, so it corresponds to L3 at best.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN03907P | SUPRICORT CREAM 0.025% w/w | Cream | Not stated in licence record |
| SIN04897P | FLUNOLONE-V CREAM 0.25 mg/g | Cream | Not stated in licence record |
| SIN14597P | CETRAXAL PLUS EAR DROPS SOLUTION | Solution | Not stated in licence record |
| SIN12607P | TRI-LUMA CREAM | Cream | Not stated in licence record |
All four licences are valid. The creams are topical, which fits skin conditions such as lichen planus.
Safety Considerations
- Disease associations flagged in the knowledge graph (not label text): sunburn, herpes simplex infections (including herpes simplex keratitis and geniculate herpes zoster), fungal eye infection and mycotic corneal ulcer, ocular tuberculosis, glaucoma, adrenocortical insufficiency and Addison disease, skin atrophy, telangiectasia and other capillary or peripheral vascular diseases. The knowledge graph also lists atopic eczema and dermatitis in this contraindication set, which conflicts with the drug's original indications. These associations must be checked against the approved product label.
- Drug interactions: The database lists 9 interacting drugs, all with unclassified severity: dexamethasone, cetirizine, citalopram, valproic acid, acetaminophen, digoxin, levothyroxine, alendronic acid and clonazepam. The clinical significance of each has not been assessed.
- Other considerations: For some other predicted indications, such as neonatal dermatomyositis, potent topical steroids raise concerns about systemic absorption and suppression of the HPA (hypothalamic-pituitary-adrenal) axis.
Please refer to the package insert for full warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The 99.42% prediction score is high, but it is the only support: there are no clinical trials or publications for hypertrophic lichen planus. The mechanism is plausible because the drug is already used for lichen disease, but this is not enough to move forward.
To proceed, the following is needed:
- Retrieve the Singapore package insert (warnings, contraindications and approved indications), since the current licence records have no indication text.
- Search for lichen planus-specific evidence, such as trials or literature on topical corticosteroids in hypertrophic lichen planus.
- Review whether the existing "lichen disease" approval already covers this subtype, which would make the new indication unnecessary.
- Consider re-prioritising alopecia areata, the only predicted indication with any clinical literature. The literature is historical, so a modern evidence review would be needed.
- Obtain detailed mechanism-of-action data.
- Assess the knowledge-graph contraindication signals and the unclassified drug interactions.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.